Karo Pharma

Karo Pharma OCF Margin

Delisted·Nov 24, 2022

The Operating Cash Flow Margin of Karo Pharma (KARO.ST) as of Oct 29, 2026 is 17.98 %. In the previous year, Operating Cash Flow Margin was 11.42 % — a change of 57.49% (higher).

OCF Margin

17.98 %

YoY

57.49%

Last updated:

Operating Cash Flow Margin of Karo Pharma is 2021 17.98 % . Operating Cash Flow Margin of Karo Pharma was 2020 11.42 % . It decreases by 57.49% higher compared to the previous year.

The Karo Pharma OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2014
-154.13 SEK
Jan 1, 2015
-75.56 SEK
Jan 1, 2016
-10.40 SEK
Jan 1, 2017
5.10 SEK
Jan 1, 2018
19.69 SEK
Jan 1, 2019
5.62 SEK
Jan 1, 2020
11.42 SEK
Jan 1, 2021
17.98 SEK
The Karo Pharma OCF Margin history
YEAROCF MarginYoY
17.98 %+57.49%
11.42 %+103.21%
5.62 %-71.46%
19.69 %+286.32%
5.10 %-149.01%
-10.40 %-86.24%
-75.56 %-50.97%
-154.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Karo Pharma Stock analysis

What does Karo Pharma do? Karo Pharma AB is a Swedish pharmaceutical company specializing in the manufacturing and distribution of over-the-counter drugs and health products. The company's history dates back to 1986 when it was founded as Karo Bioforskning. Over time, the company went through several restructurings and realignments until it finally became an independent company listed on the Stockholm Stock Exchange in 2017 under the name Karo Pharma AB. Karo Pharma's business model is based on a broad portfolio of over-the-counter drugs and health products tailored to the needs of consumers in different countries and for different indications. The product range includes pain relievers, cold remedies, medications for digestive disorders, and eye care products. In addition, the company also offers dietary supplements and other health products. Karo Pharma operates in three main segments: Consumer Healthcare, Prescription Pharmaceuticals, and Out-licensing. Consumer Healthcare focuses on over-the-counter drugs and health products for end consumers. Examples include VagiVital, a medication for the treatment of vaginal yeast infections, and MolluscumVital, a product for the removal of warts. In the Prescription Pharmaceuticals segment, Karo Pharma offers prescription drugs for specific indications, such as Eklira, used in the treatment of chronic obstructive pulmonary disease (COPD). The Out-licensing segment involves the licensing of products and technologies to other companies. Karo Pharma has a particular focus on the development of products based on natural active ingredients. For example, Prenoxdiazin, used for pain relief, is based on an extract from the root of peonies. Natural ingredients are preferred in the development of other products as well, to maximize their compatibility and effectiveness. Overall, Karo Pharma's portfolio includes more than 20 brands and over 100 products distributed in various countries. The company is headquartered in Stockholm and operates in several European countries, as well as in the United States and Canada. Karo Pharma emphasizes close collaboration with doctors and pharmacists to ensure that its products meet the needs of consumers optimally. In recent years, Karo Pharma has become the leading provider of over-the-counter drugs and health products in Scandinavia and now plans to expand its presence in other European countries. The company aims to strengthen its position as the leading provider of over-the-counter drugs and health products, with a focus on innovative and natural solutions, through a combination of organic growth and targeted acquisitions of companies with complementary products and technologies. Karo Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Karo Pharma stock

Operating Cash Flow Margin of Karo Pharma is 17.98 % in 2021.

Operating Cash Flow Margin of Karo Pharma changed from 11.42 % to 17.98 %, representing a 57.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Karo Pharma since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Karo Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Karo Pharma

All Key Metrics — Karo Pharma